Gasche C, Berstad A, Befrits R, Beglinger C, Dignass A, Erichsen K, et al. Iron deficiency anemia in inflammatory bowel disease. Imaging inflammation of the pancreatic islets in type 1 diabetes. Noninvasive imaging of pancreatic inflammation and its reversal in type 1 diabetes. Turvey SE, Swart E, Denis MC, Mahmood U, Benoist C, Weissleder R, et al. Noninvasive mapping of pancreatic inflammation in recent-onset type-1 diabetes patients. Gaglia JL, Harisinghani M, Aganj I, Wojtkiewicz GR, Hedgire S, Benoist C, et al. Early window of diabetes determinism in NOD mice, dependent on the complement receptor CRIg, identified by noninvasive imaging. 2008 Nov 57(11):2922–3.įu W, Wojtkiewicz G, Weissleder R, Benoist C, Mathis D. Big Mac Attack: Does It Play a Direct Role for Monocytes/Macrophages in Type 1 Diabetes? Diabetes. Relaxivity of Ferumoxytol at 1.5 T and 3.0 T. Knobloch G, Colgan T, Wiens CN, Wang X, Schubert T, Hernando D, et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann H-J. MRI assessment of hepatic iron clearance rates after USPIO administration in healthy adults. Storey P, Lim RP, Chandarana H, Rosenkrantz AB, Kim D, Stoffel DR, et al. Bone marrow uptake of ferumoxytol: a preliminary study in healthy human subjects. Vascular Imaging With Ferumoxytol as a Contrast Agent. ![]() Hope MD, Hope TA, Zhu C, Faraji F, Haraldsson H, Ordovas KG, et al. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study. Neuwelt EA, Várallyay CG, Manninger S, Solymosi D, Haluska M, Hunt MA, et al. Drug Safety and Availability - FDA Drug Safety Communication: FDA strengthens warnings and changes prescribing instructions to decrease the risk of serious allergic reactions with anemia drug Feraheme (ferumoxytol). A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. Hetzel D, Strauss W, Bernard K, Li Z, Urboniene A, Allen LF. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period. Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron. Vadhan-Raj S, Strauss W, Ford D, Bernard K, Boccia R, Li J, et al. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Macdougall IC, Strauss WE, McLaughlin J, Li Z, Dellanna F, Hertel J. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min. 2017 92(1):47–66.Īuerbach M, Strauss W, Auerbach S, Rineer S, Bahrain H. Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. Toth GB, Varallyay CG, Horvath A, Bashir MR, Choyke PL, Daldrup-Link HE, et al. ![]() Emerging applications for ferumoxytol as a contrast agent in MRI. 2018 Sep 6 0(ja):null.īashir MR, Bhatti L, Marin D, Nelson RC. Ferumoxytol for the treatment of iron deficiency anemia. ![]() J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. Weinstein JS, Varallyay CG, Dosa E, Gahramanov S, Hamilton B, Rooney WD, et al. Gadolinium retention in the body: what we know and what we can do. Tedeschi E, Caranci F, Giordano F, Angelini V, Cocozza S, Brunetti A. Drug Safety and Availability - FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body requires new class warnings.
0 Comments
Leave a Reply. |